Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. Dynamk Capital led the round.
Source: Press Release
Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. Dynamk Capital led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination